Huabang Health announced that its wholly-owned subsidiary Shenyang Xinma Pharmaceutical Co., Ltd. received the “Tax Handling Decision” issued by the Second Inspection Bureau of the Shenyang Municipal Taxation Bureau of the State Administration of Taxation. The tax authorities examined the source of the Xinma Pharmaceutical case from January 1, 2019 to December 31, 2024, and determined that there was an illegal fact of false invoicing. Xinma Pharmaceutical should pay a total of 385.51 million yuan in additional taxes, including a total of 5.0717 million yuan in value-added tax and surcharges and 334.334 million yuan in corporate income tax, and levied a late payment fee of 5/10,000 on a daily basis from the date of late payment until the actual payment date.

Huabang Health announced that its wholly-owned subsidiary Shenyang Xinma Pharmaceutical Co., Ltd. received the “Tax Handling Decision” issued by the Second Inspection Bureau of the Shenyang Municipal Taxation Bureau of the State Administration of Taxation. The tax authorities examined the source of the Xinma Pharmaceutical case from January 1, 2019 to December 31, 2024, and determined that there was an illegal fact of false invoicing. Xinma Pharmaceutical should pay a total of 385.51 million yuan in additional taxes, including a total of 5.0717 million yuan in value-added tax and surcharges and 334.334 million yuan in corporate income tax, and levied a late payment fee of 5/10,000 on a daily basis from the date of late payment until the actual payment date.